Brief: Prothena Reports Topline Early-Stage Trial Results Of Alzheimer’s Disease Treatment

Prothena

31/01/2023 22:41

Jan 31 (Reuters) - Prothena Corporation PLC  PRTA.O :
    * PROTHENA REPORTS TOPLINE PHASE 1 SINGLE ASCENDING DOSE
STUDY
RESULTS OF PRX005, A NOVEL ANTI-MTBR-TAU ANTIBODY FOR THE
POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
    * PROTHENA CORPORATION PLC - SINGLE DOSES OF PRX005 ACROSS
THREE
DOSE COHORTS WERE GENERALLY SAFE AND WELL TOLERATED, MEETING
PRIMARY OBJECTIVE OF STUDY
    * PROTHENA - PHASE 1 MULTIPLE ASCENDING DOSE (MAD) PORTION
OF
STUDY IS ONGOING; TOPLINE RESULTS EXPECTED BY YEAR END

Source text for Eikon:  ID:nBw7tTjZga 
Further company coverage:  PRTA.O 
 ((Reuters.Briefs@thomsonreuters.com;))